Articles related to PANCREATIC CANCER

An engineered probiotic strain delivering a modified IL-2 therapy directly within pancreatic tumors slowed tumor growth and enhanced immune activity in preclinical models. Combination studies with chemotherapy, radiotherapy, and immunotherapy showed additional activity, though human data are not yet available.

A high-sensitivity KRAS-targeted blood test detects residual pancreatic cancer missed by standard assays, suggesting current monitoring approaches may underestimate recurrence risk despite treatment.

Daraxonrasib, an oral RAS(ON) inhibitor, doubled overall survival and progression-free survival versus chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma across RAS-mutated and wild-type disease in a phase 3 trial.

A community oncologist previewed four ASCO 2026 late-breaking abstracts spanning pancreatic, prostate, lung, and sarcoma, flagging molecular testing infrastructure and toxicity coordination as key implementation questions ahead of the data readout.

Daraxonrasib produced 13.2-month median overall survival versus 6.7 months with chemotherapy in 501 previously treated metastatic pancreatic ductal adenocarcinoma patients in the phase 3 RASolute 302 trial.

“Patients treated in the Optune Pax arm had a median time to pain progression of 15.2 months compared to 9.1 months.” — PANOVA-3 Trial, FDA Approval Announcement